Related references
Note: Only part of the references are listed.NCCBM, a Nomogram Prognostic Model in Breast Cancer Patients With Brain Metastasis
Qiang Liu et al.
FRONTIERS IN ONCOLOGY (2021)
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers
Yun Song et al.
CANCER (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Breast Cancer, Version 3.2020
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
F. Montemurro et al.
ANNALS OF ONCOLOGY (2020)
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Rachel A. Freedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update
Naren Ramakrishna et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Brain Metastases in Newly Diagnosed Breast Cancer A Population-Based Study
Allison M. Martin et al.
JAMA ONCOLOGY (2017)
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial
Ahmad Awada et al.
JAMA ONCOLOGY (2016)
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
I. E. Krop et al.
ANNALS OF ONCOLOGY (2015)
Metastatic breast cancer subtypes and central nervous system metastases
C. Aversa et al.
BREAST (2014)
Risk factors and survival outcomes in patients with brain metastases from breast cancer
A. M. Minisini et al.
CLINICAL & EXPERIMENTAL METASTASIS (2013)
Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype
Nils D. Arvold et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden
G. Frisk et al.
BRITISH JOURNAL OF CANCER (2012)
Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival
F. Heitz et al.
ANNALS OF ONCOLOGY (2011)
Extracranial metastatic patterns on occurrence of brain metastases
Duong Anh Vuong et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
Harri Sihto et al.
BREAST CANCER RESEARCH (2011)
Patterns of relapse in breast cancer: changes over time
Rinat Yerushalmi et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Brain metastases admissions in Sweden between 1987 and 2006
K. E. Smedby et al.
BRITISH JOURNAL OF CANCER (2009)
Sites of Distant Recurrence and Clinical Outcomes in Patients With Metastatic Triple-negative Breast Cancer High Incidence of Central Nervous System Metastases
Nancy U. Lin et al.
CANCER (2008)
Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis
Elise M. Pelletier et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Primary breast cancer phenotypes associated with propensity for central nervous system metastases
Yee-Lu Tham et al.
CANCER (2006)
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
BC Pestalozzi et al.
ANNALS OF ONCOLOGY (2006)
Spectrum of breast cancer metastasis in BRCA1 mutation carriers:: highly increased incidence of brain metastases
L Albiges et al.
ANNALS OF ONCOLOGY (2005)
Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system
JS Barnholtz-Sloan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Risk factors for brain relapse in patients with metastatic breast cancer
K Slimane et al.
ANNALS OF ONCOLOGY (2004)
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
DW Andrews et al.
LANCET (2004)
Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma
LJ Schouten et al.
CANCER (2002)
Share Paper
